1. Development of a Novel Anti-Mouse CCR2 Monoclonal Antibody (C2Mab-6) by N-Terminal Peptide Immunization
    Tomohiro Tanaka et al, 2022, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy CrossRef
  2. Development of a Novel Anti-EpCAM Monoclonal Antibody for Various Applications
    Guanjie Li et al, 2022, Antibodies CrossRef
  3. TrMab-6 Exerts Antitumor Activity in Mouse Xenograft Models of Breast Cancers
    Tomohiro Tanaka et al, 2022, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy CrossRef
  4. Establishment of Novel Anti-Mouse CCR3 Monoclonal Antibodies (C3Mab-6 and C3Mab-7) by N-terminal Peptide Immunization
    Teizo Asano et al, 2022, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy CrossRef
  5. TgMab-2: An Anti-human T Cell Immunoglobulin and Immunoreceptor Tyrosine-Based Inhibitory Motif Domain Monoclonal Antibody for Immunocytochemistry
    Masaki Saito et al, 2022, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy CrossRef
  6. Development of an Anti-human CCR2 Monoclonal Antibody (C2Mab-9) by N-Terminal Peptide Immunization
    Tomohiro Tanaka et al, 2022, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy CrossRef
  7. Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
    Paolo Tarantino et al, 2022, CA: A Cancer Journal for Clinicians CrossRef
  8. Anti‑HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma
    Teizo Asano et al, 2021, Oncology Reports CrossRef
  9. C3Mab-3: A Monoclonal Antibody for Mouse CC Chemokine Receptor 3 for Flow Cytometry
    Teizo Asano et al, 2022, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy CrossRef
  10. Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?
    Dimitrios Zardavas, 2022, Expert Opinion on Investigational Drugs CrossRef